26 research outputs found
A role for STEAP2 in prostate cancer progression
Prostate adenocarcinoma is the second most
frequent cancer worldwide and is one of the leading causes
of male cancer-related deaths. However, it varies greatly in
its behaviour, from indolent non-progressive disease to
metastatic cancers with high associated mortality. The aim
of this study was to identify predictive biomarkers for
patients with localised prostate tumours most likely to
progress to aggressive disease, to facilitate future tailored
clinical treatment and identify novel therapeutic targets.
The expression of 602 genes was profiled using oligoarrays,
across three prostate cancer cell lines: CA-HPV-10,
LNCaP and PC3, qualitatively identifying several potential
prognostic biomarkers. Of particular interest was six
transmembrane epithelial antigen of the prostate (STEAP) 1
and STEAP 2 which was subsequently analysed further in
prostate cancer tissue samples following optimisation of an
RNA extraction method from laser captured cells isolated
from formalin-fixed paraffin-embedded biopsy samples.
Quantitative analysis of STEAP1 and 2 gene expression
were statistically significantly associated with the metastatic
cell lines DU145 and PC3 as compared to the normal
prostate epithelial cell line, PNT2. This expression pattern
was also mirrored at the protein level in the cells. Furthermore,
STEAP2 up-regulation was observed within a
small patient cohort and was associated with those that had
locally advanced disease. Subsequent mechanistic studies
in the PNT2 cell line demonstrated that an over-expression
of STEAP2 resulted in these normal prostate cells gaining
an ability to migrate and invade, suggesting that STEAP2
expression may be a crucial molecule in driving the invasive
ability of prostate cancer cells